These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 3480043)

  • 1. Phase I trial of homoharringtonine in children with refractory leukemia.
    Tan CT; Luks E; Bacha DM; Steinherz P; Steinherz L; Mondora A
    Cancer Treat Rep; 1987 Dec; 71(12):1245-8. PubMed ID: 3480043
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I clinical investigation of homoharringtonine.
    Legha SS; Keating M; Picket S; Ajani JA; Ewer M; Bodey GP
    Cancer Treat Rep; 1984 Sep; 68(9):1085-91. PubMed ID: 6478448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Homoharringtonine: an effective new drug for remission induction in refractory nonlymphoblastic leukemia.
    Warrell RP; Coonley CJ; Gee TS
    J Clin Oncol; 1985 May; 3(5):617-21. PubMed ID: 3889229
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I clinical evaluation of diaziquone in childhood cancer.
    Ettinger LJ; Siegel SE; Belasco JB; Evans AE; Ruccione KS; Jamin DC; Rohrbaugh TM; Higgins GR
    Cancer Treat Rep; 1985 Mar; 69(3):323-7. PubMed ID: 3856480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Harringtonine in acute leukemias. Clinical analysis of 31 cases.
    Chin Med J (Engl); 1977 Sep; 3(5):319-24. PubMed ID: 411635
    [No Abstract]   [Full Text] [Related]  

  • 6. Phase I study of aziridinylbenzoquinone (AZQ, NSC 182986) in children with cancer.
    Tan CT; Hancock CH; Mondora A; Hoffman NW
    Cancer Res; 1984 Feb; 44(2):831-5. PubMed ID: 6692381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy.
    Quintás-Cardama A; Kantarjian H; Garcia-Manero G; O'Brien S; Faderl S; Estrov Z; Giles F; Murgo A; Ladie N; Verstovsek S; Cortes J
    Cancer; 2007 Jan; 109(2):248-55. PubMed ID: 17154172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I--II evaluation of a new anthracycline antibiotic, aclacinomycin A, in adults with refractory leukemia.
    Warrell RP; Arlin ZA; Kempin SJ; Young CW
    Cancer Treat Rep; 1982 Aug; 66(8):1619-23. PubMed ID: 6955022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mitoxantrone in the treatment of relapsed and refractory acute leukemia.
    Moore JO; Olsen GA
    Semin Oncol; 1984 Sep; 11(3 Suppl 1):41-6. PubMed ID: 6385265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I trial of amifostine (WR-2721) and melphalan in children with refractory cancer.
    Adamson PC; Balis FM; Belasco JE; Lange B; Berg SL; Blaney SM; Craig C; Poplack DG
    Cancer Res; 1995 Sep; 55(18):4069-72. PubMed ID: 7664282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I-II trial of mitoxantrone in acute leukemia.
    Arlin ZA; Silver R; Cassileth P; Armentrout S; Gams R; Daghestani A; Coleman M; Schoch I; Dukart G
    Cancer Treat Rep; 1985 Jan; 69(1):61-4. PubMed ID: 3855386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A pilot study of high-dose 1-beta-D-arabinofuranosylcytosine for acute leukemia and refractory lymphoma: clinical response and pharmacology.
    Early AP; Preisler HD; Slocum H; Rustum YM
    Cancer Res; 1982 Apr; 42(4):1587-94. PubMed ID: 6949642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Homoharringtonine is safe and effective for patients with acute myelogenous leukemia.
    Feldman E; Arlin Z; Ahmed T; Mittelman A; Puccio C; Chun H; Cook P; Baskind P
    Leukemia; 1992 Nov; 6(11):1185-8. PubMed ID: 1434802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II studies of homoharringtonine in patients with advanced malignant melanoma; sarcoma; and head and neck, breast, and colorectal carcinomas.
    Ajani JA; Dimery I; Chawla SP; Pinnamaneni K; Benjamin RS; Legha SS; Krakoff IH
    Cancer Treat Rep; 1986 Mar; 70(3):375-9. PubMed ID: 3955548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I dose-finding and pharmacokinetic study of subcutaneous semisynthetic homoharringtonine (ssHHT) in patients with advanced acute myeloid leukaemia.
    Lévy V; Zohar S; Bardin C; Vekhoff A; Chaoui D; Rio B; Legrand O; Sentenac S; Rousselot P; Raffoux E; Chast F; Chevret S; Marie JP
    Br J Cancer; 2006 Aug; 95(3):253-9. PubMed ID: 16847470
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I clinical trial of orally administered 4-demethoxydaunorubicin (idarubicin) with pharmacokinetic and in vitro drug sensitivity testing in children with refractory leukemia.
    Pui CH; de Graaf SS; Dow LW; Rodman JH; Evans WE; Alpert BS; Murphy SB
    Cancer Res; 1988 Sep; 48(18):5348-52. PubMed ID: 3165708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I trial of a novel diphtheria toxin/granulocyte macrophage colony-stimulating factor fusion protein (DT388GMCSF) for refractory or relapsed acute myeloid leukemia.
    Frankel AE; Powell BL; Hall PD; Case LD; Kreitman RJ
    Clin Cancer Res; 2002 May; 8(5):1004-13. PubMed ID: 12006512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amsacrine in refractory acute leukemia.
    Griffin JD; Maguire ME; Mayer RJ
    Cancer Treat Rep; 1985; 69(7-8):787-9. PubMed ID: 3860296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I trial of homoharringtonine administered by prolonged continuous infusion.
    Neidhart JA; Young DC; Kraut E; Howinstein B; Metz EN
    Cancer Res; 1986 Feb; 46(2):967-9. PubMed ID: 3940656
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II evaluation of diglycoaldehyde (Inox) in children with acute leukemia: a children's cancer study group report.
    Higgins GR; Finklestein J; Krivit W; Hammond D
    Cancer Treat Rep; 1980; 64(4-5):625-8. PubMed ID: 7427952
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.